Geron Corporation Stockholders Encouraged to Contact Securities Law Firm about Investigation PR Newswire DALLAS, March 24, 2014 DALLAS, March 24, 2014 /PRNewswire/ -- Securities lawyers at Deans & Lyons announce an investigation of the board of Geron Corporation (NASDAQ: GERN). Concerned GERN investors who purchased between June 16, 2013 and March 11, 2014 are encouraged to contact securities attorney Hamilton Lindley by clicking here. "After the March 12, 2014 announcement that the FDA put Geron's Investigational New Drug application for imetelstat on full clinical hold, stock plummeted more than 60%," said securities lawyer Hamilton Lindley. "Our potential shareholder lawsuit will seek to ensure that all relevant information is disclosed to Geron Corporation shareholders." Deans & Lyons has significant experience representing shareholders in securities lawsuits nationwide. GERN stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at email@example.com or 877-819-8033 with questions or concerns. Hamilton Lindley DEANS & LYONS LLP 325 North Saint Paul Street, Suite 1500 Dallas, TX 75201 Phone: 214-736-7861 Fax: 214-965-8505 Toll-free: 877-819-8033 firstname.lastname@example.org www.deanslyons.com SOURCE Deans & Lyons LLP Website: http://www.deanslyons.com
Geron Corporation Stockholders Encouraged to Contact Securities Law Firm about Investigation
Press spacebar to pause and continue. Press esc to stop.